Cargando…
Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein
Human noroviruses are the major viral cause of acute gastroenteritis around the world. Although norovirus symptoms are in most cases mild and self-limited, severe and prolonged symptoms can occur in the elderly and in immunocompromised individuals. Thus, there is a great need for the development of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641292/ https://www.ncbi.nlm.nih.gov/pubmed/36389818 http://dx.doi.org/10.3389/fimmu.2022.1040836 |
_version_ | 1784826066800476160 |
---|---|
author | Ford-Siltz, Lauren A. Tohma, Kentaro Alvarado, Gabriela S. Kendra, Joseph A. Pilewski, Kelsey A. Crowe, James E. Parra, Gabriel I. |
author_facet | Ford-Siltz, Lauren A. Tohma, Kentaro Alvarado, Gabriela S. Kendra, Joseph A. Pilewski, Kelsey A. Crowe, James E. Parra, Gabriel I. |
author_sort | Ford-Siltz, Lauren A. |
collection | PubMed |
description | Human noroviruses are the major viral cause of acute gastroenteritis around the world. Although norovirus symptoms are in most cases mild and self-limited, severe and prolonged symptoms can occur in the elderly and in immunocompromised individuals. Thus, there is a great need for the development of specific therapeutics that can help mitigate infection. In this study, we sought to characterize a panel of human monoclonal antibodies (mAbs; NORO-123, -115, -273A, -263, -315B, and -250B) that showed carbohydrate blocking activity against the current pandemic variant, GII.4 Sydney 2012. All antibodies tested showed potent neutralization against GII.4 Sydney virus in human intestinal enteroid culture. While all mAbs recognized only GII.4 viruses, they exhibited differential binding patterns against a panel of virus-like particles (VLPs) representing major and minor GII.4 variants spanning twenty-five years. Using mutant VLPs, we mapped five of the mAbs to variable antigenic sites A (NORO-123, -263, -315B, and -250B) or C (NORO-115) on the major capsid protein. Those mapping to the antigenic site A showed blocking activity against multiple variants dating back to 1987, with one mAb (NORO-123) showing reactivity to all variants tested. NORO-115, which maps to antigenic site C, showed reactivity against multiple variants due to the low susceptibility for mutations presented by naturally-occurring variants at the proposed binding site. Notably, we show that cross-blocking and neutralizing antibodies can be elicited against variable antigenic sites. These data provide new insights into norovirus immunity and suggest potential for the development of cross-protective vaccines and therapeutics. |
format | Online Article Text |
id | pubmed-9641292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96412922022-11-15 Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein Ford-Siltz, Lauren A. Tohma, Kentaro Alvarado, Gabriela S. Kendra, Joseph A. Pilewski, Kelsey A. Crowe, James E. Parra, Gabriel I. Front Immunol Immunology Human noroviruses are the major viral cause of acute gastroenteritis around the world. Although norovirus symptoms are in most cases mild and self-limited, severe and prolonged symptoms can occur in the elderly and in immunocompromised individuals. Thus, there is a great need for the development of specific therapeutics that can help mitigate infection. In this study, we sought to characterize a panel of human monoclonal antibodies (mAbs; NORO-123, -115, -273A, -263, -315B, and -250B) that showed carbohydrate blocking activity against the current pandemic variant, GII.4 Sydney 2012. All antibodies tested showed potent neutralization against GII.4 Sydney virus in human intestinal enteroid culture. While all mAbs recognized only GII.4 viruses, they exhibited differential binding patterns against a panel of virus-like particles (VLPs) representing major and minor GII.4 variants spanning twenty-five years. Using mutant VLPs, we mapped five of the mAbs to variable antigenic sites A (NORO-123, -263, -315B, and -250B) or C (NORO-115) on the major capsid protein. Those mapping to the antigenic site A showed blocking activity against multiple variants dating back to 1987, with one mAb (NORO-123) showing reactivity to all variants tested. NORO-115, which maps to antigenic site C, showed reactivity against multiple variants due to the low susceptibility for mutations presented by naturally-occurring variants at the proposed binding site. Notably, we show that cross-blocking and neutralizing antibodies can be elicited against variable antigenic sites. These data provide new insights into norovirus immunity and suggest potential for the development of cross-protective vaccines and therapeutics. Frontiers Media S.A. 2022-10-25 /pmc/articles/PMC9641292/ /pubmed/36389818 http://dx.doi.org/10.3389/fimmu.2022.1040836 Text en Copyright © 2022 Ford-Siltz, Tohma, Alvarado, Kendra, Pilewski, Crowe and Parra https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ford-Siltz, Lauren A. Tohma, Kentaro Alvarado, Gabriela S. Kendra, Joseph A. Pilewski, Kelsey A. Crowe, James E. Parra, Gabriel I. Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein |
title | Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein |
title_full | Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein |
title_fullStr | Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein |
title_full_unstemmed | Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein |
title_short | Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein |
title_sort | cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641292/ https://www.ncbi.nlm.nih.gov/pubmed/36389818 http://dx.doi.org/10.3389/fimmu.2022.1040836 |
work_keys_str_mv | AT fordsiltzlaurena crossreactiveneutralizinghumanmonoclonalantibodiesmappingtovariableantigenicsitesonthenorovirusmajorcapsidprotein AT tohmakentaro crossreactiveneutralizinghumanmonoclonalantibodiesmappingtovariableantigenicsitesonthenorovirusmajorcapsidprotein AT alvaradogabrielas crossreactiveneutralizinghumanmonoclonalantibodiesmappingtovariableantigenicsitesonthenorovirusmajorcapsidprotein AT kendrajosepha crossreactiveneutralizinghumanmonoclonalantibodiesmappingtovariableantigenicsitesonthenorovirusmajorcapsidprotein AT pilewskikelseya crossreactiveneutralizinghumanmonoclonalantibodiesmappingtovariableantigenicsitesonthenorovirusmajorcapsidprotein AT crowejamese crossreactiveneutralizinghumanmonoclonalantibodiesmappingtovariableantigenicsitesonthenorovirusmajorcapsidprotein AT parragabrieli crossreactiveneutralizinghumanmonoclonalantibodiesmappingtovariableantigenicsitesonthenorovirusmajorcapsidprotein |